APO Research
Talk to an analyst

APO RESEARCH · REPORT

Humanized Monoclonal Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Humanized Monoclonal Antibody Drugs Industry Growth and Trends Forecast to 2032

23 December 2025111 pages

Choose your research edition.

Industry ResearchHumanized Monoclonal Antibody Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Humanized Monoclonal Antibody Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Humanized Monoclonal Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Humanized Monoclonal Antibody Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Humanized Monoclonal Antibody Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

According to APO Research, the global Humanized Monoclonal Antibody Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Humanized Monoclonal Antibody Drugs market include Innovent Bio, Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Qilu Pharma, Novartis, Merck & Co and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Humanized Monoclonal Antibody Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Humanized Monoclonal Antibody Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Humanized Monoclonal Antibody Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Humanized Monoclonal Antibody Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Humanized Monoclonal Antibody Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Humanized Monoclonal Antibody Drugs Market by Company

Innovent Bio

Takeda

Teva

Sun Pharmaceutical

Johnson & Johnson

Qilu Pharma

Novartis

Merck & Co

Roche

Eli Lilly & Co

Pfizer

Beigene

GlaxoSmithKline

Biogen

AbbVie

AstraZeneca

UCB

Gilead Sciences

Humanized Monoclonal Antibody Drugs Segment by Type

Ixekizumab

Vedolizumab

Risenqizumab

Trastuzumab

Pembrolizumab

Farisimab

Bevacizumab

Orelizumab

Omalizumab

Other

Humanized Monoclonal Antibody Drugs Segment by Application

Cancers

Inflammatory Condition

Autoimmune Diseases

Humanized Monoclonal Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Humanized Monoclonal Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Humanized Monoclonal Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Humanized Monoclonal Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Humanized Monoclonal Antibody Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Humanized Monoclonal Antibody Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Humanized Monoclonal Antibody Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Humanized Monoclonal Antibody Drugs Market Share by Region (2021-2026) Table 4. Global Humanized Monoclonal Antibody Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Humanized Monoclonal Antibody Drugs Market Share by Region (2027-2032) Table 6. Global Humanized Monoclonal Antibody Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Humanized Monoclonal Antibody Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Humanized Monoclonal Antibody Drugs Market Size Share by Type (2021-2026) Table 9. Global Humanized Monoclonal Antibody Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Humanized Monoclonal Antibody Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Humanized Monoclonal Antibody Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Humanized Monoclonal Antibody Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Humanized Monoclonal Antibody Drugs Market Size Share by Application (2021-2026) Table 24. Global Humanized Monoclonal Antibody Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Humanized Monoclonal Antibody Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Humanized Monoclonal Antibody Drugs Industry Trends Table 37. Humanized Monoclonal Antibody Drugs Industry Drivers Table 38. Humanized Monoclonal Antibody Drugs Industry Opportunities and Challenges Table 39. Humanized Monoclonal Antibody Drugs Industry Restraints Table 40. Global Humanized Monoclonal Antibody Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Humanized Monoclonal Antibody Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Humanized Monoclonal Antibody Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Humanized Monoclonal Antibody Drugs Key Company Headquarters & Area Served Table 44. Global Humanized Monoclonal Antibody Drugs Company, Product Type & Application Table 45. Global Humanized Monoclonal Antibody Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Humanized Monoclonal Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Innovent Bio Company Information Table 49. Innovent Bio Business Overview Table 50. Innovent Bio Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Innovent Bio Humanized Monoclonal Antibody Drugs Product Portfolio Table 52. Innovent Bio Recent Development Table 53. Takeda Company Information Table 54. Takeda Business Overview Table 55. Takeda Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Takeda Humanized Monoclonal Antibody Drugs Product Portfolio Table 57. Takeda Recent Development Table 58. Teva Company Information Table 59. Teva Business Overview Table 60. Teva Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Teva Humanized Monoclonal Antibody Drugs Product Portfolio Table 62. Teva Recent Development Table 63. Sun Pharmaceutical Company Information Table 64. Sun Pharmaceutical Business Overview Table 65. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product Portfolio Table 67. Sun Pharmaceutical Recent Development Table 68. Johnson & Johnson Company Information Table 69. Johnson & Johnson Business Overview Table 70. Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Johnson & Johnson Humanized Monoclonal Antibody Drugs Product Portfolio Table 72. Johnson & Johnson Recent Development Table 73. Qilu Pharma Company Information Table 74. Qilu Pharma Business Overview Table 75. Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Qilu Pharma Humanized Monoclonal Antibody Drugs Product Portfolio Table 77. Qilu Pharma Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Novartis Humanized Monoclonal Antibody Drugs Product Portfolio Table 82. Novartis Recent Development Table 83. Merck & Co Company Information Table 84. Merck & Co Business Overview Table 85. Merck & Co Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Merck & Co Humanized Monoclonal Antibody Drugs Product Portfolio Table 87. Merck & Co Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Roche Humanized Monoclonal Antibody Drugs Product Portfolio Table 92. Roche Recent Development Table 93. Eli Lilly & Co Company Information Table 94. Eli Lilly & Co Business Overview Table 95. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product Portfolio Table 97. Eli Lilly & Co Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Pfizer Humanized Monoclonal Antibody Drugs Product Portfolio Table 102. Pfizer Recent Development Table 103. Beigene Company Information Table 104. Beigene Business Overview Table 105. Beigene Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Beigene Humanized Monoclonal Antibody Drugs Product Portfolio Table 107. Beigene Recent Development Table 108. GlaxoSmithKline Company Information Table 109. GlaxoSmithKline Business Overview Table 110. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product Portfolio Table 112. GlaxoSmithKline Recent Development Table 113. Biogen Company Information Table 114. Biogen Business Overview Table 115. Biogen Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Biogen Humanized Monoclonal Antibody Drugs Product Portfolio Table 117. Biogen Recent Development Table 118. AbbVie Company Information Table 119. AbbVie Business Overview Table 120. AbbVie Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. AbbVie Humanized Monoclonal Antibody Drugs Product Portfolio Table 122. AbbVie Recent Development Table 123. AstraZeneca Company Information Table 124. AstraZeneca Business Overview Table 125. AstraZeneca Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. AstraZeneca Humanized Monoclonal Antibody Drugs Product Portfolio Table 127. AstraZeneca Recent Development Table 128. UCB Company Information Table 129. UCB Business Overview Table 130. UCB Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. UCB Humanized Monoclonal Antibody Drugs Product Portfolio Table 132. UCB Recent Development Table 133. Gilead Sciences Company Information Table 134. Gilead Sciences Business Overview Table 135. Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Gilead Sciences Humanized Monoclonal Antibody Drugs Product Portfolio Table 137. Gilead Sciences Recent Development Table 138. North America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2026) Table 141. North America Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Humanized Monoclonal Antibody Drugs Market Share Forecast by Country (2027-2032) Table 143. Europe Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2026) Table 146. Europe Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Humanized Monoclonal Antibody Drugs Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2026) Table 151. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Share Forecast by Country (2027-2032) Table 153. Latin America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2026) Table 156. Latin America Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Humanized Monoclonal Antibody Drugs Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2026) Table 161. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Humanized Monoclonal Antibody Drugs Product Image Figure 3. Global Humanized Monoclonal Antibody Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Humanized Monoclonal Antibody Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Humanized Monoclonal Antibody Drugs Market Share by Region (2021-2032) Figure 7. North America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Ixekizumab Image Figure 13. Global Ixekizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Vedolizumab Image Figure 15. Global Vedolizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Risenqizumab Image Figure 17. Global Risenqizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Trastuzumab Image Figure 19. Global Trastuzumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Pembrolizumab Image Figure 21. Global Pembrolizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Farisimab Image Figure 23. Global Farisimab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Bevacizumab Image Figure 25. Global Bevacizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Orelizumab Image Figure 27. Global Orelizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Omalizumab Image Figure 29. Global Omalizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Other Image Figure 31. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Global Humanized Monoclonal Antibody Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 33. Global Humanized Monoclonal Antibody Drugs Market Share by Type 2025 VS 2032 Figure 34. North America Humanized Monoclonal Antibody Drugs Market Size Share by Type (2021-2032) Figure 35. Europe Humanized Monoclonal Antibody Drugs Market Size Share by Type (2021-2032) Figure 36. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Share by Type (2021-2032) Figure 37. Latin America Humanized Monoclonal Antibody Drugs Market Size Share by Type (2021-2032) Figure 38. Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Share by Type (2021-2032) Figure 39. Cancers Image Figure 40. Global Cancers Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Inflammatory Condition Image Figure 42. Global Inflammatory Condition Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. Autoimmune Diseases Image Figure 44. Global Autoimmune Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Global Humanized Monoclonal Antibody Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 46. Global Humanized Monoclonal Antibody Drugs Market Share by Application 2025 VS 2032 Figure 47. North America Humanized Monoclonal Antibody Drugs Market Size Share by Application (2021-2032) Figure 48. Europe Humanized Monoclonal Antibody Drugs Market Size Share by Application (2021-2032) Figure 49. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Share by Application (2021-2032) Figure 50. Latin America Humanized Monoclonal Antibody Drugs Market Size Share by Application (2021-2032) Figure 51. Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Share by Application (2021-2032) Figure 52. Global Top 5 and 10 Humanized Monoclonal Antibody Drugs Players Market Share by Revenue in 2025 Figure 53. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 54. North America Humanized Monoclonal Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. North America Humanized Monoclonal Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. North America Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032) Figure 57. Europe Humanized Monoclonal Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Humanized Monoclonal Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032) Figure 60. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032) Figure 63. Latin America Humanized Monoclonal Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Humanized Monoclonal Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032) Figure 66. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 67. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 68. Middle East & Africa Humanized Monoclonal Antibody Drugs Market Share by Country (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Ixekizumab
  • Vedolizumab
  • Risenqizumab
  • Trastuzumab
  • Pembrolizumab
  • Farisimab
  • Bevacizumab
  • Orelizumab
  • Omalizumab
  • Other
Applications
  • Cancers
  • Inflammatory Condition
  • Autoimmune Diseases
Companies covered
  • Innovent Bio
  • Takeda
  • Teva
  • Sun Pharmaceutical
  • Johnson & Johnson
  • Qilu Pharma
  • Novartis
  • Merck & Co
  • Roche
  • Eli Lilly & Co
  • Pfizer
  • Beigene
  • GlaxoSmithKline
  • Biogen
  • AbbVie
  • AstraZeneca
  • UCB
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Humanized Monoclonal Antibody Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Humanized Monoclonal Antibody Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Humanized Monoclonal Antibody Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Humanized Monoclonal Antibody Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
  8. 1.5.1 North America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size Growth Rate (2021-2032)
2 Humanized Monoclonal Antibody Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Ixekizumab
  3. 2.1.2 Vedolizumab
  4. 2.1.3 Risenqizumab
  5. 2.1.4 Trastuzumab
  6. 2.1.5 Pembrolizumab
  7. 2.1.6 Farisimab
  8. 2.1.7 Bevacizumab
  9. 2.1.8 Orelizumab
  10. 2.1.9 Omalizumab
  11. 2.1.10 Other
  12. 2.2 Global Humanized Monoclonal Antibody Drugs Market Size by Type
  13. 2.2.1 Global Humanized Monoclonal Antibody Drugs Market Size Overview by Type (2021-2032)
  14. 2.2.2 Global Humanized Monoclonal Antibody Drugs Historic Market Size Review by Type (2021-2026)
  15. 2.2.3 Global Humanized Monoclonal Antibody Drugs Market Size Forecasted by Type (2027-2032)
  16. 2.3 Global Humanized Monoclonal Antibody Drugs Market Size by Regions
  17. 2.3.1 North America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026)
  18. 2.3.2 Europe Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026)
  19. 2.3.3 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026)
  20. 2.3.4 South America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026)
  21. 2.3.5 Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Breakdown by Type (2021-2026)
3 Humanized Monoclonal Antibody Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Cancers
  3. 3.1.2 Inflammatory Condition
  4. 3.1.3 Autoimmune Diseases
  5. 3.2 Global Humanized Monoclonal Antibody Drugs Market Size by Application
  6. 3.2.1 Global Humanized Monoclonal Antibody Drugs Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Humanized Monoclonal Antibody Drugs Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Humanized Monoclonal Antibody Drugs Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Humanized Monoclonal Antibody Drugs Market Size by Regions
  10. 3.3.1 North America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Humanized Monoclonal Antibody Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Humanized Monoclonal Antibody Drugs Industry Trends
  2. 4.2 Humanized Monoclonal Antibody Drugs Industry Drivers
  3. 4.3 Humanized Monoclonal Antibody Drugs Industry Opportunities and Challenges
  4. 4.4 Humanized Monoclonal Antibody Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Humanized Monoclonal Antibody Drugs Revenue (2021-2026)
  2. 5.2 Global Humanized Monoclonal Antibody Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Humanized Monoclonal Antibody Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Humanized Monoclonal Antibody Drugs Company, Product Type & Application
  5. 5.5 Global Humanized Monoclonal Antibody Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Humanized Monoclonal Antibody Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Humanized Monoclonal Antibody Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Humanized Monoclonal Antibody Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Innovent Bio
  2. 6.1.1 Innovent Bio Company Information
  3. 6.1.2 Innovent Bio Business Overview
  4. 6.1.3 Innovent Bio Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Innovent Bio Humanized Monoclonal Antibody Drugs Product Portfolio
  6. 6.1.5 Innovent Bio Recent Developments
  7. 6.2 Takeda
  8. 6.2.1 Takeda Company Information
  9. 6.2.2 Takeda Business Overview
  10. 6.2.3 Takeda Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Takeda Humanized Monoclonal Antibody Drugs Product Portfolio
  12. 6.2.5 Takeda Recent Developments
  13. 6.3 Teva
  14. 6.3.1 Teva Company Information
  15. 6.3.2 Teva Business Overview
  16. 6.3.3 Teva Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Teva Humanized Monoclonal Antibody Drugs Product Portfolio
  18. 6.3.5 Teva Recent Developments
  19. 6.4 Sun Pharmaceutical
  20. 6.4.1 Sun Pharmaceutical Company Information
  21. 6.4.2 Sun Pharmaceutical Business Overview
  22. 6.4.3 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product Portfolio
  24. 6.4.5 Sun Pharmaceutical Recent Developments
  25. 6.5 Johnson & Johnson
  26. 6.5.1 Johnson & Johnson Company Information
  27. 6.5.2 Johnson & Johnson Business Overview
  28. 6.5.3 Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Johnson & Johnson Humanized Monoclonal Antibody Drugs Product Portfolio
  30. 6.5.5 Johnson & Johnson Recent Developments
  31. 6.6 Qilu Pharma
  32. 6.6.1 Qilu Pharma Company Information
  33. 6.6.2 Qilu Pharma Business Overview
  34. 6.6.3 Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Qilu Pharma Humanized Monoclonal Antibody Drugs Product Portfolio
  36. 6.6.5 Qilu Pharma Recent Developments
  37. 6.7 Novartis
  38. 6.7.1 Novartis Company Information
  39. 6.7.2 Novartis Business Overview
  40. 6.7.3 Novartis Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Novartis Humanized Monoclonal Antibody Drugs Product Portfolio
  42. 6.7.5 Novartis Recent Developments
  43. 6.8 Merck & Co
  44. 6.8.1 Merck & Co Company Information
  45. 6.8.2 Merck & Co Business Overview
  46. 6.8.3 Merck & Co Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Merck & Co Humanized Monoclonal Antibody Drugs Product Portfolio
  48. 6.8.5 Merck & Co Recent Developments
  49. 6.9 Roche
  50. 6.9.1 Roche Company Information
  51. 6.9.2 Roche Business Overview
  52. 6.9.3 Roche Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Roche Humanized Monoclonal Antibody Drugs Product Portfolio
  54. 6.9.5 Roche Recent Developments
  55. 6.10 Eli Lilly & Co
  56. 6.10.1 Eli Lilly & Co Company Information
  57. 6.10.2 Eli Lilly & Co Business Overview
  58. 6.10.3 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product Portfolio
  60. 6.10.5 Eli Lilly & Co Recent Developments
  61. 6.11 Pfizer
  62. 6.11.1 Pfizer Company Information
  63. 6.11.2 Pfizer Business Overview
  64. 6.11.3 Pfizer Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Pfizer Humanized Monoclonal Antibody Drugs Product Portfolio
  66. 6.11.5 Pfizer Recent Developments
  67. 6.12 Beigene
  68. 6.12.1 Beigene Company Information
  69. 6.12.2 Beigene Business Overview
  70. 6.12.3 Beigene Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Beigene Humanized Monoclonal Antibody Drugs Product Portfolio
  72. 6.12.5 Beigene Recent Developments
  73. 6.13 GlaxoSmithKline
  74. 6.13.1 GlaxoSmithKline Company Information
  75. 6.13.2 GlaxoSmithKline Business Overview
  76. 6.13.3 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product Portfolio
  78. 6.13.5 GlaxoSmithKline Recent Developments
  79. 6.14 Biogen
  80. 6.14.1 Biogen Company Information
  81. 6.14.2 Biogen Business Overview
  82. 6.14.3 Biogen Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Biogen Humanized Monoclonal Antibody Drugs Product Portfolio
  84. 6.14.5 Biogen Recent Developments
  85. 6.15 AbbVie
  86. 6.15.1 AbbVie Company Information
  87. 6.15.2 AbbVie Business Overview
  88. 6.15.3 AbbVie Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 AbbVie Humanized Monoclonal Antibody Drugs Product Portfolio
  90. 6.15.5 AbbVie Recent Developments
  91. 6.16 AstraZeneca
  92. 6.16.1 AstraZeneca Company Information
  93. 6.16.2 AstraZeneca Business Overview
  94. 6.16.3 AstraZeneca Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 AstraZeneca Humanized Monoclonal Antibody Drugs Product Portfolio
  96. 6.16.5 AstraZeneca Recent Developments
  97. 6.17 UCB
  98. 6.17.1 UCB Company Information
  99. 6.17.2 UCB Business Overview
  100. 6.17.3 UCB Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 UCB Humanized Monoclonal Antibody Drugs Product Portfolio
  102. 6.17.5 UCB Recent Developments
  103. 6.18 Gilead Sciences
  104. 6.18.1 Gilead Sciences Company Information
  105. 6.18.2 Gilead Sciences Business Overview
  106. 6.18.3 Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Gilead Sciences Humanized Monoclonal Antibody Drugs Product Portfolio
  108. 6.18.5 Gilead Sciences Recent Developments
7 North America
  1. 7.1 North America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Humanized Monoclonal Antibody Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst